Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity-Reference-Cited by-同舟云学术

Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity

Published:2019-06-06 Issue:1 Volume:187 Page:93-104
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Jiménez‐Solas Tamara¹²^ORCID,López‐Cadenas Félix¹²,Aires‐Mejía Irene¹²,Caballero‐Berrocal Juan Carlos¹²^ORCID,Ortega Rebeca²,Redondo Alba María¹²,Sánchez‐Guijo Fermín¹²,Muntión Sandra¹²,García‐Martín Luís¹²,Albarrán Beatriz³,Alonso José María³,Del Cañizo Consuelo²,Hernández‐Hernández Ángel²⁴^ORCID,Díez‐Campelo María¹²^ORCID

Affiliation:

1. Servicio de Hematología Hospital Universitario de Salamanca Salamanca Spain

2. Instituto de Investigación Biomédica de Salamanca (IBSAL) Salamanca Spain

3. Servicio de Hematología Complejo Asistencial Universitario de Palencia Palencia Spain

4. Departamento de Bioquímica y Biología Molecular Universidad de Salamanca Salamanca Spain

Funder

Fundación Ramón Areces

Novartis

Ministerio de Economía y Competitividad

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16013

Reference51 articles.

1. Evidence‐ and consensus‐based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology;Alessandrino E.P.;Haematologica,2002

2. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)

3. Safety and efficacy, including event‐free survival, of deferasirox versus placebo in iron‐overloaded patients with low‐ and int‐1‐risk myelodysplastic syndromes (MDS): outcomes from the randomized, Double‐Blind Telesto Study;Angelucci E.;Blood,2018

4. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

5. Reactive oxygen species in oncogenic transformation;Behrend L.;Molecular Mechanisms of Signalling,2003

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of reactive oxygen species in myelodysplastic syndromes;Cellular & Molecular Biology Letters;2024-04-14

2. Deferasirox Causes Leukaemia Cell Death through Nrf2-Induced Ferroptosis;Antioxidants;2024-03-29

3. ATF4-activated parkin induction contributes to deferasirox-mediated cytoprotection in Parkinson’s disease;Toxicological Research;2022-12-08

4. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells;Therapeutic Advances in Hematology;2022-01

5. DNA Methylation Is Correlated with Oxidative Stress in Myelodysplastic Syndrome—Relevance as Complementary Prognostic Biomarkers;Cancers;2021-06-23